TCRX TScan Therapeutics, Inc.
Nasdaq · SEC CIK 1783328 · EDGAR
- Bought, last 12 months
- $145.6K 1 purchases by 1 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 95 since 2021-07-16, latest 2026-05-22 16:08
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Lynx1 Capital Management LP | 10% | $145.6K | — |
Transactions 28
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-12-23 | 2025-12-19+ | TCRX | Lynx1 Capital Management LP | 10% | P - Purchase | $0.9 | +161.8K | 8.01M | +2% | +$145.6K |
| MI | 2025-05-21 | 2025-05-19+ | TCRX | Lynx1 Capital Management LP | 10% | P - Purchase | $1.20 | +2.59M | 6.75M | +62% | +$3.11M |
| MI | 2024-12-16 | 2024-12-12+ | TCRX | Nichols Weston | 10% | P - Purchase | $2.93 | +131.8K | 5.26M | +3% | +$385.7K |
| I | 2024-11-19 | 2024-11-15 | TCRX | Nichols Weston | 10% | P - Purchase | $4.34 | +947 | 5.23M | +0.0% | +$4,110 |
| 2024-09-24 | 2024-09-23 | TCRX | Klencke Barbara | Dir | P - Purchase | $5.29 | +5,000 | 45.0K | +12% | +$26.4K | |
| M | 2024-08-27 | 2024-08-23+ | TCRX | Klencke Barbara | Dir | P - Purchase | $5.61 | +10.0K | 35.0K | +40% | +$56.1K |
| D | 2024-08-27 | 2024-08-23 | TCRX | ZDRAVESKI ZORAN | See Remarks | S - Sale+OE | $5.78 | -164.7K | 4,716 | -97% | -$951.9K |
| DM | 2024-08-27 | 2024-08-23 | TCRX | ZDRAVESKI ZORAN | See Remarks | M - OptEx | $3.38 | +157.2K | 67.1K | New | +$531.5K |
| M | 2023-12-21 | 2023-12-18+ | TCRX | BARBERICH TIMOTHY J | Dir | P - Purchase | $4.89 | +29.1K | 67.0K | +77% | +$142.6K |
| 2023-12-18 | 2023-12-14 | TCRX | Klencke Barbara | Dir | P - Purchase | $5.08 | +5,000 | 30.0K | +20% | +$25.4K | |
| 2023-06-06 | 2023-06-02 | TCRX | BARBERICH TIMOTHY J | Dir | P - Purchase | $2.63 | +37.9K | 37.9K | New | +$99.6K | |
| MI | 2023-06-02 | 2023-05-31 | TCRX | Lynx1 Capital Management LP | 10% | S - Sale | $2.52 | -25.4K | 5.22M | -0.5% | -$63.9K |
| M | 2022-12-29 | 2022-12-27+ | TCRX | Silver Brian M. | CFO | P - Purchase | $1.53 | +6,000 | 32.9K | +22% | +$9,189 |
| M | 2022-05-20 | 2022-05-18 | TCRX | SOUTHWELL DAVID P | CEO, Dir | P - Purchase | $3.59 | +25.0K | 171.6K | +17% | +$89.8K |
| MI | 2022-05-12 | 2022-05-10+ | TCRX | 667, L.P. | Dir, 10% | P - Purchase | $1.88 | +1.36M | 1.75M | +351% | +$2.56M |
| 2022-03-28 | 2022-03-24 | TCRX | Silver Brian M. | CFO | P - Purchase | $3.40 | +15.0K | 26.9K | +126% | +$51.0K | |
| D | 2021-12-27 | 2021-12-23 | TCRX | SOUTHWELL DAVID P | CEO, Dir | M - OptEx | $1.97 | +48.7K | 146.6K | +50% | +$95.9K |
| 2021-09-27 | 2021-09-23 | TCRX | ZDRAVESKI ZORAN | CLO | P - Purchase | $7.48 | +4,716 | 4,716 | New | +$35.3K | |
| 2021-09-22 | 2021-09-21 | TCRX | Silver Brian M. | CFO | P - Purchase | $6.32 | +5,000 | 11.9K | +73% | +$31.6K | |
| M | 2021-09-22 | 2021-09-20+ | TCRX | MacBeath Gavin | CSO | P - Purchase | $6.22 | +5,000 | 49.7K | +11% | +$31.1K |
| 2021-09-13 | 2021-09-09 | TCRX | Silver Brian M. | CFO | P - Purchase | $8.48 | +5,885 | 6,885 | +588% | +$49.9K | |
| 2021-09-09 | 2021-09-08 | TCRX | SOUTHWELL DAVID P | CEO, Dir | P - Purchase | $8.73 | +11.0K | 97.9K | +13% | +$96.0K | |
| 2021-08-31 | 2021-08-27 | TCRX | Desmarais William | Chief Business Off | P - Purchase | $9.08 | +2,500 | 2,500 | New | +$22.7K | |
| DI | 2021-07-22 | 2021-07-20 | TCRX | Westphal Christoph H | 10% | C - Cnv Deriv | — | +1.15M | 1.15M | New | — |
| DI | 2021-07-22 | 2021-07-20 | TCRX | Westphal Christoph H | 10% | P - Purchase | $15.00 | +133.3K | 1.28M | +12% | +$2.00M |
| 2021-07-22 | 2021-07-20 | TCRX | Silver Brian M. | CFO | P - Purchase | $15.00 | +1,000 | 1,000 | New | +$15.0K | |
| D | 2021-07-22 | 2021-07-20 | TCRX | BARBERICH TIMOTHY J | Dir | C - Cnv Deriv | — | +33.3K | 33.3K | New | — |
| DMI | 2021-07-22 | 2021-07-20 | TCRX | 667, L.P. | Dir | P - Purchase | $15.00 | +1.43M | 1.32M | New | +$21.38M |
Purchase Sale Sale after option exercise All abbreviations